Can Individualized Dosimetry Improve Treatment Efficacy for 177Lu-DOTATATE (D) Therapy in Primary Site Agnostic Neuroendocrine Tumors?
Wong, R.K., Yeung, I.W.T., Driscoll, B., Shessel, A., Publicover, J., Beauregard, J.M., Myrehaug, S.D., Laidley, D., Juergens, R., Metser, U., Veit-Haibach, P., Ezzat, S., Lajkosz, K.
Published in International journal of radiation oncology, biology, physics (01.10.2024)
Published in International journal of radiation oncology, biology, physics (01.10.2024)
Get full text
Journal Article
Quantifying Renal And Tumor Doses with Individualized Dosimetry In 177Lu DOTATATE Therapy – What Difference Does It Make?
Wong, R., Laidley, D., Myrehaug, S.D., Brierley, J., Juergens, R., Yeung, I.W.T., Breen, S., Driscoll, B., Shessel, A., Farncombe, T., Zukotynski, K., Stodilka, R., Caldwell, C.B., Liu, Z., Valliant, J., McCann, J., Metser, U., Mohan, R., Beauregard, J.M., Jaffray, D.A.
Published in International journal of radiation oncology, biology, physics (01.09.2019)
Published in International journal of radiation oncology, biology, physics (01.09.2019)
Get full text
Journal Article
Résultats de qualité de vie liée à la santé, douleur et tolérance de l’étude de phase 3 VISION du 177Lu-PSMA-617 chez des patients atteints d’un CPRCm
Fizazi, K., Flippot, R., Hermann, K., Krause, B.J., Rahbar, K., Chi, K.N., Morris, M.J., Sartor, O., Tagawa, S.T., Kendi, A.T., Vogelzang, N., Calais, J., Nagarajah, J., Wei, X.X., Koshkin, V.S., Beauregard, J.M., Chang, B., DeSilvio, M., Messmann, R.A., de Bono, J.
Published in Médecine nucléaire : imagerie fonctionelle et métabolique (01.03.2022)
Published in Médecine nucléaire : imagerie fonctionelle et métabolique (01.03.2022)
Get full text
Journal Article